| Literature DB >> 36104717 |
Rui Qin1, Feng-Ming You1, Qian Zhao2, Xin Xie3, Cheng Peng1, Gu Zhan4, Bo Han5.
Abstract
Regulated cell death (RCD) is a critical and active process that is controlled by specific signal transduction pathways and can be regulated by genetic signals or drug interventions. Meanwhile, RCD is closely related to the occurrence and therapy of multiple human cancers. Generally, RCD subroutines are the key signals of tumorigenesis, which are contributed to our better understanding of cancer pathogenesis and therapeutics. Indole alkaloids derived from natural sources are well defined for their outstanding biological and pharmacological properties, like vincristine, vinblastine, staurosporine, indirubin, and 3,3'-diindolylmethane, which are currently used in the clinic or under clinical assessment. Moreover, such compounds play a significant role in discovering novel anticancer agents. Thus, here we systemically summarized recent advances in indole alkaloids as anticancer agents by targeting different RCD subroutines, including the classical apoptosis and autophagic cell death signaling pathways as well as the crucial signaling pathways of other RCD subroutines, such as ferroptosis, mitotic catastrophe, necroptosis, and anoikis, in cancer. Moreover, we further discussed the cross talk between different RCD subroutines mediated by indole alkaloids and the combined strategies of multiple agents (e.g., 3,10-dibromofascaplysin combined with olaparib) to exhibit therapeutic potential against various cancers by regulating RCD subroutines. In short, the information provided in this review on the regulation of cell death by indole alkaloids against different targets is expected to be beneficial for the design of novel molecules with greater targeting and biological properties, thereby facilitating the development of new strategies for cancer therapy.Entities:
Keywords: Anoikis; Apoptosis; Autophagy; Cancer; Ferroptosis; Indole alkaloids; Mitotic catastrophe; Necroptosis; Regulated cell death (RCD); Target therapy
Mesh:
Substances:
Year: 2022 PMID: 36104717 PMCID: PMC9471064 DOI: 10.1186/s13045-022-01350-z
Source DB: PubMed Journal: J Hematol Oncol ISSN: 1756-8722 Impact factor: 23.168